The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)

NCT ID: NCT00145691

Last Updated: 2007-03-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-09-30
• Study Completion Date: 2006-10-31

Brief Summary

We intend to conduct a phase III b trial to verify Oxcarbazepine's effect in agitation and aggression in patients with dementia. We designed the study as a randomized, double-blind, placebo-controlled multi center trial. Hundred patients will be included. The treatment period will be eight weeks, with a further follow up of four weeks.

The primary outcome measure will be the reduction in aggression and agitation as measured by means of NPI-NH-subscale agitation / aggression (Neuropsychiatric Inventory, Nursing Home Version). Secondary outcomes are reduction in aggression as measured by BARS (Behavior Agitation Rating Scale)and reduction in the burden to health-care personnel as measured by NPI-NH.

Detailed Description

Inclusion criteria: Patients of either gender, 55 years of age or older, living in a nursing home diagnosed with or a strong suspicion of dementia of Alzheimer's type or vascular origin, and BPSD in form of agitation / aggression as measured by subscale of NPI-NH and BARS.

Exclusion criteria: Patients that have any other kind of dementia as FTD, PD or LBD; patients with hepatic or renal failure, or diseases that make it impossible to follow the study schedule; patients on antiepileptics or antipsychotics.

Conditions

Agitation Aggression in Dementia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Oxcarbazepine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Alzheimer's dementia, vascular dementia or mixed forms of both according to ICD10 (F00, F01) criteria.
• The patient is 55 years of age or older.
• Residents at a nursing home and who have been there for at least 4 weeks prior to inclusion.
• Signed informed consent by the patient or the relatives signed agreement that they have no reservations against patient's participation in the study.
• At least one week history of agitation or aggression, score 6 or more in NPI-NH-subscale agitation/aggression.

Exclusion Criteria

• Previous intolerability or known hypersensitivity to Oxcarbazepine or its equivalents
• Low sodium serum levels <135 mmol/L
• Severe impaired renal function (creatinine clearance <30 ml/min, calculated with Cockroft + Gault's formula)
• Hepatic failure (transaminases (g-GT and ALAT > 3 times upper normal limit).
• Patients with AV-block II and III and all kinds of arrhythmia necessitating a treatment.
• Severe somatic diseases that afford a change of medication and will compromise the attendance to the study.
• Patients on cyclosporine.
• Patients in need of strong analgesics like opioids as codeines
• Patients taking carisoprodol
• Alcohol or drug abuse during the last 12 months (used a higher dosage than prescribed)
• The patient has been on ChEIs or memantine for less than 3 months or any change in the dosage during the last 2 weeks.
• The patient is taking antiepileptics or antipsychotics (may be included two weeks after the use of antipsychotics has been ended).
• The patient is taking MAOI or lithium
• The patient with a dementia of type PDD, FTD or DLB
• The patients with a severe or acute neurological disease (e.g. epilepsy, acute CVE, severe Parkinson's disease, acute confusion) or a severe psychiatric disorder like bipolar disorder, schizophrenia...
• The patients who have participated in another clinical trial during the last 3 months.
• The patients who have been randomized to the same study before.

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sykehuset Innlandet HF

OTHER

Sponsor Role: lead

Principal Investigators

Oskar H Sommer, MD

Role: PRINCIPAL_INVESTIGATOR

Sykehuset Innlandet HF

Locations

Sykehuset Innlandet HF

Reinsvoll, Oppland, Norway

Countries

Norway

References

Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, Engedal K. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord. 2009;27(2):155-63. doi: 10.1159/000199236. Epub 2009 Feb 2.

Reference Type: DERIVED

PMID: 19182483 (View on PubMed)

Other Identifiers

Sponsor's Protocol Code: 1500

Identifier Type: -

Identifier Source: secondary_id

EudraCT number: 2004-005266-20

Identifier Type: -

Identifier Source: org_study_id